Johnson & Johnson is reassuring investors that its pharmaceutical business will grow through the loss of exclusivity (LOE) of Stelara (ustekinumab), anticipated in the second half of 2023. While the diversified health care company generated steady growth in the third quarter, despite currency and inflation headwinds, persistent macroeconomic challenges coupled with the big upcoming patent exclusivity loss will create difficult business conditions for J&J to navigate next year.
With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway
Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.
More from Earnings
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.